Dual-colour HER2/chromosome 17 chromogenic in situ hybridisation assay enables accurate assessment of HER2 genomic status in gastric cancer and has potential utility in HER2 testing of biopsy samples

Benedict Yan, Ee Xuan Yau, Shoa Nian Choo, Chee Wee Ong, Kol Jia Yong, Brendan Pang, Manuel Salto-Tellez

Research output: Contribution to journalArticlepeer-review

32 Citations (Scopus)

Abstract

Determination of HER2 protein expression by immunohistochemistry (IHC) and genomic status by fluorescent in situ hybridisation (FISH) are important in identifying a subset of high HER2-expressing gastric cancers that might respond to trastuzumab. Although FISH is considered the standard for determination of HER2 genomic status, brightfield ISH is being increasingly recognised as a viable alternative. Also, the impact of HER2 protein expression/genomic heterogeneity on the accuracy of HER2 testing has not been well studied in the context of gastric biopsy samples.
Original languageEnglish
Pages (from-to)880-3
Number of pages4
JournalJournal of Clinical Pathology
Volume64
Issue number10
DOIs
Publication statusPublished - Oct 2011

Keywords

  • Chromosomes, Human, Pair 17
  • Receptor, erbB-2
  • Chi-Square Distribution
  • Humans
  • In Situ Hybridization, Fluorescence
  • Biopsy
  • Predictive Value of Tests
  • Gene Amplification
  • False Negative Reactions
  • In Situ Hybridization
  • Stomach Neoplasms
  • Singapore
  • Tumor Markers, Biological
  • Immunohistochemistry

Fingerprint

Dive into the research topics of 'Dual-colour HER2/chromosome 17 chromogenic in situ hybridisation assay enables accurate assessment of HER2 genomic status in gastric cancer and has potential utility in HER2 testing of biopsy samples'. Together they form a unique fingerprint.

Cite this